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INTRODUCTION
Genetic and environmental factors contribute to the pathogenesis of neurologic diseases (Al-Chalabi and Hardiman, 2013; Chin-Chan et al., 2015; Kamel, 2013; Olsson et al., 2017; Rappaport and Smith, 2010; Tshala-Katumbay et al., 2015) . Extensive genomic studies have identified genetic determinants that affect neurologic disorders. Environmental factors affecting disease pathogenesis have also been identified. For example, microbial metabolites and changes in melatonin levels driven by seasonal variations in night length affect CNS inflammation (Farez et al., 2015; Rothhammer et al., 2016 Rothhammer et al., , 2018 . However, there is still an unmet need for methods to systematically evaluate the effects of environmental factors on CNS pathology and the mechanisms involved.
Astrocytes are CNS-resident cells that play important roles in tissue development and homeostasis, and they can also contribute to the pathogenesis of neurologic disorders Mayo et al., 2014; Rothhammer and Quintana, 2015) . Indeed, astrocytes and microglia control CNS inflammation and neurodegeneration (Colonna and Butovsky, 2017; Wheeler and Quintana, 2018) . Accordingly, genetic variants linked to neurologic disorders modulate astrocyte and microglia activity (Raj et al., 2014; Sims et al., 2017) . We and others recently showed that commensal bacterium metabolites regulate microglia and astrocyte responses, suggesting that environmental factors modulate CNS-resident cells to contribute to the pathogenesis of neurologic diseases (Erny et al., 2015; Rothhammer et al., 2016 Rothhammer et al., , 2018 Sampson et al., 2016; Thion et al., 2018) . However, the identity of most of these environmental factors and the mechanisms involved are still unknown.
Here we describe a multidisciplinary approach to identify environmental factors that boost astrocyte-driven inflammation and define novel pathways involved in the regulation of astrocyte pro-inflammatory activities. (legend continued on next page) et al., Li et al., 2015) . To exploit the advantages offered by zebrafish for the study of neurologic disease, we developed a model of CNS inflammation based on the treatment of zebrafish embryos with pro-inflammatory E. coli K12 lipopolysaccharide (LPS) in combination with cuprizone, an inducer of demyelination (Matsushima and Morell, 2001 ; Figure 1A ). LPS and cuprizone treatment led to a reduction in myelin protein zero (mpz) expression ( Figure 1B) , recapitulating similar observations made in murine models of cuprizone-induced demyelination (Liu et al., 2010) . Cuprizone-induced demyelination in mice is associated with the activation of CNS-resident glial cells such as astrocytes and microglia (Matsushima and Morell, 2001) . Indeed, we found that LPS and cuprizone treatment induced the expression of genes associated with inflammation, such as nos2a, il1b, il17a/f1, ccl20, and il10 ( Figure 1C ). To focus on the response of astrocyte-related cells to LPS and cuprizone treatment, we used Tg(gfap::egfp) zebrafish in which EGFP expression is driven by the glial fibrillary acidic protein (gfap) promoter (Bernardos and Raymond, 2006) . This reporter line labels zebrafish radial glia, which provide a model to study signaling pathways functional in astrocytes and other CNS-resident mammalian cells (Hui et al., 2010; Lyons and Talbot, 2014) . The analysis of EGFP + (Gfap + ) cells showed that LPS and cuprizone treatment upregulated the expression of nos2a (Figure 1D ), the zebrafish ortholog of inducible nitric oxide synthase (iNOS) that has been linked to astrocyte pro-inflammatory and neurodegenerative activities (Rabinovich et al., 2016; Sorbara et al., 2014) . Thus, LPS and cuprizone induces a radial glia phenotype that resembles disease-promoting astrocytes in neurologic disorders.
Environmental Exposures Boost Astrocyte Pathogenicity
Environmental factors affect the pathogenesis of neurologic diseases, but methods for their systematic investigation are still needed (Al-Chalabi and Hardiman, 2013; Chin-Chan et al., 2015; Kamel, 2013; Olsson et al., 2017; Rappaport and Smith, 2010; Tshala-Katumbay et al., 2015) . We used the zebrafish model of LPS and cuprizone-induced inflammation to systematically evaluate the effects of environmental chemicals on disease-promoting astrocyte functions ( Figure 1E ). In these studies, we used the ToxCast chemical inventory established by the United States Environmental Protection Agency (EPA), which includes a broad collection of representative chemicals from multiple sources, ranging from industrial and consumer products to food additives (Sipes et al., 2013) . First, we performed a bioinformatic analysis of the ToxCast chemical inventory to identify compounds that modulate signaling pathways previously linked to neurodegeneration and inflammation in genetic and functional studies. Specifically, we focused on the identification of compounds that could potentially modify signaling associated with the aryl hydrocarbon receptor (AHR; Rothhammer et al., 2016) , DR5 (Aktas et al., 2005) , interferon g (IFNg; Zamvil and Steinman, 2003) , transforming growth factor b1 (TGF-b1; Shull et al., 1992) , interleukin-1a (IL-1a; , IL-6 (Glass et al., 2010) , STAT3 (Anderson et al., 2016) , and JAK3 (Levine et al., 2007) . Our bioinformatic screening of 976 molecules in the ToxCast database identified 75 candidate compounds, which were then evaluated for their effects on nos2a expression in LPS and cuprizone-treated zebrafish ( Figure 1F ; Figure S1A ; Table S1 ). Of these 75 candidates, 5 compounds increased nos2a expression in LPS and cuprizone-treated zebrafish (Figures 1F and 1G) .
To evaluate the relevance of these findings for the modulation of CNS inflammation in mammals, we analyzed the effect of these compounds on Nos2 expression in primary murine astrocytes activated in vitro with IL-1b and tumor necrosis factor alpha (TNF-a). These cytokines induce iNOS expression in astrocytes in vitro (Hewett et al., 1994) and contribute to CNS inflammation in vivo (Lock et al., 2002) . We found that the herbicide linuron and methyl carbamate, which is used by the textile, polymer, and pharmaceutical industries, boost Nos2 expression in murine astrocytes activated in vitro with pro-inflammatory IL-1b and TNF-a ( Figure 1H ). Thus, in the context of inflammation, methyl carbamate and linuron boost evolutionarily conserved signaling pathways in mouse astrocytes that induce a disease-promoting phenotype.
Linuron Boosts UPR Activation to Amplify Astrocyte Pathogenic Activities Linuron was recently banned in Europe because of its potential risk to mammals (European Food Safety Authority, 2016). Thus, we focused our studies on the mechanisms by which linuron modulates astrocyte function; the study of these mechanisms may identify signaling pathways that control astrocyte responses. Bioinformatic analysis of the EPA gene expression database identified multiple interactions of linuron with the unfolded protein response (UPR) ( Figure 2A ; Table S2 ; Bettigole and Glimcher, 2015) . The UPR is activated by three endoplasmic reticulum (ER)-bound transmembrane receptors: protein kinase RNA-like ER kinase (PERK), activating transcription factor 6 (ATF6), and IRE1a (Bettigole and Glimcher, 2015) . Our bioinformatic analysis identified two candidate pathways for the activation of the UPR by linuron: PERK signaling, leading to activation of CCAAT/enhancer-binding protein homologous protein (CHOP, encoded by Ddit3), and IRE1a signaling, leading to phosphorylation of IRE1a, which removes a stop codon-containing intron in the Xbp1 transcript and enables the translation of a functional full-length XBP1 transcription factor Yoshida et al., 2001) .
We first analyzed the UPR in astrocytes activated with IL-1b and TNF-a, pro-inflammatory cytokines considered important contributors to multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) pathogenesis (Lin and Edelson, 2017; Valentin-Torres et al., 2016) . Astrocyte treatment with IL-1b and TNF-a activated the transcription factor nuclear factor kB (NF-kB) ( Figure 2B ), associated with astrocyte pro-inflammatory and neurotoxic activities (Liddelow and Barres, 2017) . Moreover, IL-1b and TNF-a triggered IRE1a phosphorylation, which was highest 20-120 min after activation, preceding the increase in full-length (active) XBP1 detected at 240 min. Of note, astrocyte activation with IL-1b and TNF-a did not alter CHOP expression, ruling out a major contribution of PERK in cytokine-induced UPR activation in astrocytes ( Figures 2B-2D ). Taken together, these findings suggest that pro-inflammatory stimuli relevant to MS activate IRE1a-XBP1 signaling in astrocytes.
We then investigated the effects of linuron on the UPR and the pro-inflammatory activities of astrocytes. Linuron synergized with IL-1b and TNF-a to induce unfolded protein accumulation in astrocytes ( Figure 2E ) and Xbp1 splicing ( Figure 2F ) up to 24 hr after activation, when spliced Xbp1 levels are decreased in cytokine-only treated astrocytes. Linuron also boosted the expression of pro-inflammatory genes in astrocytes such as Nos2, Il6, Csf2, and Ccl2 ( Figure 2G ). However, XBP1 activation was not induced by perfluorononanoic acid (PFNA), methyl carbamate, or other stimuli such as serum and glucose deprivation or extracellular ATP, suggesting specificity in the stressors that activate this pathway in astrocytes (Figures S1B-S1E).
To investigate the mechanism by which linuron and the UPR control pro-inflammatory gene expression in astrocytes, we studied the effects of PERK (GSK2656157) and IRE1a (STF-083010) inhibitors on Nos2 expression (Keestra-Gounder et al., 2016) . IRE1a inhibition suppressed Nos2 expression upregulation induced by cytokines and potentiated by linuron ( Figure 2H ); PERK inhibition had no effect. Moreover, linuron boosted XBP1 recruitment to the regulatory regions of genes associated with astrocyte pathogenic activities, such as Nos2 (linked to neurotoxicity; Hewett et al., 1994) and Csf2 (linked to microglia activation; Becher et al., 2016) ( Figure 2I ). Indeed, XBP1 transactivated the Nos2 promoter in reporter assays to similar levels as NF-kB p65 ( Figure 2J ), a known driver of Nos2 expression . Taken together, these findings suggest that IRE1a-XBP1 signaling drives pro-inflammatory astrocyte responses and that linuron boosts these pathogenic activities by enhancing the UPR.
Linuron Boosts IRE1a-XBP1 Activation via Sigmar1
To identify the mechanism by which linuron boosts XBP1 activation, we searched the EPA ToxCast inventory for molecules that interact with linuron and are linked to the UPR. We identified the ligand-activated ER chaperone Sigmar1 as a candidate molecule mediating the boost of the UPR by linuron ( Figure 3A ; Sipes et al., 2013; Watanabe et al., 2016) . Interestingly, Sigmar1 is reported to enhance the UPR by stabilizing active phosphorylated IRE1a (P-IRE1a) (Hayashi and Su, 2007; Mori et al., 2013) . Thus, we hypothesized that linuron boosts XBP1-driven pro-inflammatory gene expression in astrocytes by stabilizing P-IRE1a through a Sigmar1-dependent mechanism. In support of this hypothesis, linuron increased the interaction of Sigmar1 with IRE1a in co-immunoprecipitation studies; this increased Sigmar1:IRE1a interaction was lost upon deletion of the Sigmar1 ligand binding domain ( Figure 3B ).
We then investigated the role of Sigmar1 in the enhancement of XBP1-driven pro-inflammatory gene expression in astrocytes by linuron. Linuron boosted IRE1a activation induced in astrocytes by IL-1b and TNF-a 1 hr after stimulation; this boost in IRE1a activation was suppressed when the Sigmar1-specific inhibitor BD-1063 was used ( Figure 3C ). In agreement with the increased IRE1a activation, linuron increased XBP1 activation 1 hr after stimulation with IL-1b and TNF-a, a time point when XBP1 activation is not yet detected at the protein level in cytokine-only treated astrocytes ( Figure 3C , compare with Figure 2B ). Sigmar1 inhibition suppressed this boost in XBP1 and NF-kB activation induced by linuron and cytokine activation ( Figure 3C ). Similarly, Sigmar1 inhibition abrogated the stabilization of spliced Xbp1 transcripts induced by linuron 24 hr after treatment with IL-1b and TNF-a, a time point when Xbp1 activation returns to baseline levels in cytokine-only-treated astrocytes ( Figure 3D , compare with Figure 2F ). Consequently, Sigmar1 inhibition suppressed the synergism detected between IL-1b, TNF-a, and linuron in inducing the expression of Nos2, Csf2, Ccl2, and Il-6 expression in astrocytes and Nos2 promoter activation (G) qPCR in neonatal astrocytes after 24 hr treatment. n = 6-9 per condition, n = 4 for the Csf2 linuron condition; one-way ANOVA, Bonferroni post-test, performed on ln-normalized data for Nos2, Il6, and Csf2. (H) qPCR of Nos2 expression in neonatal primary mouse astrocytes. n = 6 per condition, n = 3 for the GSK2656157 condition; one-way ANOVA, Holm-Sidak post-test. (I) Left: predicted XBP1 and p65 binding sites in the murine Nos2 and Csf2 promoters. Right: ChIP-qPCR of XBP1 and p65 recruitment to Nos2 and Csf2 promoters in neonatal primary mouse astrocytes. n = 5 for p65 vehicle, n = 2-3 for linuron, n = 6 otherwise; Kruskal-Wallis non-parametric ANOVA, uncorrected Dunn's test (Csf2, XBP1 site 2) or one-sample t test (otherwise). (J) HEK293 luciferase reporter assay at the indicated hours post transfection (hpt). n = 5-6 per group; one-way ANOVA, Dunnett post-test. All data are shown as mean ± SEM. In all cases, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not statistically significant, p > 0.05. See also Figure S1 and Table S2 .
( Figures 3E and 3F ). Collectively, these findings suggest that linuron enhances the interaction of Sigmar1 with P-IRE1a to promote its stabilization, boosting the IRE1a-XBP1-driven expression of genes that contribute to astrocyte pathogenic activities in CNS inflammation and neurodegeneration.
Genomic Control of Disease-Promoting Astrocyte Activities by IRE1a-XBP1 Signaling Astrocytes play important roles in the pathogenesis of MS and EAE (Locatelli et al., 2018; Mayo et al., 2014; Rothhammer et al., 2016 Rothhammer et al., , 2018 Rothhammer and Quintana, 2015) . Our studies of the mechanism of action of linuron on astrocytes identified IRE1a-XBP1 signaling as a candidate regulator of astrocyte pathogenic activities. Thus, we investigated the role of IRE1a-XBP1 signaling in astrocytes in the EAE model of MS.
We detected increased expression of the XBP1 target gene Edem1 (Lee et al., 2003) in astrocytes isolated 22 days after EAE induction ( Figure 4A ). Ddit3 and Atf6 expression were unaffected, suggesting that PERK and ATF6 are not major UPR activators in astrocytes during EAE. Indeed, IRE1a blockade with STF-083010 suppressed Nos2, Csf2, and Edem1 expression induced by IL-1b and TNF-a in adult murine astrocytes in culture, supporting a role of IRE1a in inducing XBP1-driven pro-inflammatory responses in adult astrocytes ( Figure S1F ).
Chromatin immunoprecipitation (ChIP) analyses detected increased XBP1 recruitment to the Nos2 promoter concomitant with Nos2 expression in astrocytes during EAE ( Figure 4B ), suggesting that XBP1 promotes the expression of iNOS and other molecules that contribute to astrocyte pro-inflammatory activities. Indeed, the analysis of astrocytes during EAE by wholegenome ChIP followed by sequencing (ChIP-seq) detected XBP1 recruitment to its target genes Edem1 and Dnajb9 (Lee et al., 2003) and also to genes linked to immune activation, such as Csf2 ( Figure S2 ; Table S3 ). Taken together, these findings suggest that IRE1a-XBP1 signaling drives disease-promoting genomic programs in astrocytes during EAE. To evaluate the role of IRE1a-XBP1 signaling in astrocytes during EAE, we performed perturbation studies in which we knocked down Xbp1 and Ern1 (coding for IRE1a) in astrocytes using lentivirus-delivered small hairpin RNAs (shRNAs) expressed under control of the Gfap promoter ( Figures S3A-S3C ). Knockdown of Xbp1 or Ern1 in astrocytes ameliorated EAE ( Figure 4C ) but did not affect the T cell response or the number of astrocytes or microglia ( Figures S3D and S3E) . Similarly, Xbp1 or Ern1 inactivation in astrocytes by CRISPR/Cas9-based deletion also ameliorated EAE ( Figures  S4A-S4C ). However, inactivation of Eif2ak3 (coding for PERK) in astrocytes did not significantly affect EAE, suggesting that PERK signaling is not a major driver of astrocyte pathogenic activities in this experimental paradigm (Figures S4D and S4E) .
The analysis of the transcriptional profile of astrocytes by qPCR and RNA sequencing (RNA-seq) showed that Xbp1 knockdown decreased Nos2 expression and the activation of inflammation-associated pathways (Figures 4D-4G; Tables S4  and S5 ). Further support for a pro-inflammatory role of XBP1 in astrocytes during EAE was provided by studies using the assay for transposase-accessible chromatin in combination with highthroughput sequencing (ATAC-seq) . Following Xbp1 knockdown, we detected decreased chromatin accessibility in the XBP1-driven target genes Edem1 and Dnajb9 and in multiple pathways associated with inflammation (Figure 4H; Table S6 ). Collectively, these findings demonstrate that IRE1a-XBP1 signaling drives astrocyte-intrinsic pro-inflammatory activities during EAE.
Finally, we investigated the effect of boosting IRE1a-XBP1 signaling by linuron on EAE. Linuron administration worsened EAE; this worsening was suppressed when Xbp1 or Sigmar1 was inactivated in astrocytes by CRISPR/Cas9-based deletion (Figures 4I, S4B, and S5A). Xbp1 and Sigmar1 inactivation also suppressed the upregulation of pro-inflammatory gene expression induced by linuron in astrocytes (Figures 4J and 4K) but did not affect the number of astrocytes, microglia, or T cells in the CNS ( Figures S5B and S5C ). Hence, linuron acts via Sigmar1 to drive IRE1a-XBP1-dependent mechanisms in astrocytes that promote CNS inflammation during EAE.
XBP1 in Astrocytes Controls Monocytes and Microglia during EAE
Astrocytes control microglial activation and the recruitment of inflammatory monocytes to the CNS (Rothhammer and Quintana, 2015; Wheeler and Quintana, 2018) . Indeed, microglia and inflammatory monocytes are dominant cell types encountered in MS lesions; their presence and activation correlates with the emergence of tissue damage, and the suppression of monocyte recruitment to the CNS interferes with disease progression in MS experimental animal models (Ajami et al., 2011; Dendrou et al., 2015; Huitinga et al., 1990) . Thus, we investigated the effects of XBP1 signaling in astrocytes on the response of monocytes and microglia during EAE ( Figure 5A ). Xbp1 knockdown in astrocytes decreased the recruitment of peripheral inflammatory monocytes to the CNS and their expression of genes associated with inflammation (e.g., NF-kB) ( Figures 5B-5E ). In addition, Xbp1 knockdown in astrocytes decreased innate immune signaling and the expression of chemokines and cytokines in microglia ( Figures 5F-5H ).
In line with our previous observations, CRISPR/Cas9-based deletion of Xbp1 or Sigmar1 in astrocytes suppressed the linuron-induced upregulation of pro-inflammatory gene expression in microglia ( Figure 5I ). Thus, IRE1a-XBP1 signaling in astrocytes controls the pro-inflammatory response of microglia and monocytes during EAE and its exacerbation by linuron.
IRE1a-XBP1 Signaling in Astrocytes Is Upregulated in MS Finally, we evaluated the effects of the UPR in human astrocytes. Activation with TNF-a and IL-1b induced NOS2 expression in primary human astrocytes ( Figure 6A ) as well as XBP1 activation, as determined by the increased abundance of the spliced XBP1 transcript ( Figure 6B ). Linuron boosted NOS2 expression in human astrocytes; this boost was blocked with the IRE1a inhibitor STF-083010 ( Figures 6A and 6B) .
To evaluate the potential contribution of IRE1a-XBP1 signaling in astrocytes to human neurologic disease, we analyzed CNS samples from MS patients. Compared with healthy control tissue, MS samples from lesions and normal-appearing white matter (NAWM) presented increased XBP1 activation, as indicated by the abundance of spliced XBP1 transcripts ( Figure 6C ). Immunofluorescence studies detected increased astrocytespecific IRE1a activation in NAWM and normal-appearing gray matter (NAGM) from MS samples ( Figures 6D, 6E , and S6A); neurons, oligodendrocytes, and CD14 + cells (microglia and recruited monocytes) showed little or no P-IRE1a ( Figure S6A ). Moreover, using an antibody specific for the spliced, active form of XBP1 (XBP1s), we detected increased abundance of active XBP1s in astrocytes from MS samples in NAWM and NAGM ( Figures 6F and 6G ; Figures S6B and S6C) . Interestingly, although we had detected increased XBP1 activation when we analyzed MS lesions by PCR in bulk ( Figure 6C ), we did not detect increased P-IRE1a or XBP1s in astrocytes located in MS lesions. These findings suggested that, in MS lesions, XBP1 is activated in other cell types besides astrocytes. Indeed, although, in NAWM and NAGM, astrocytes were the most abundant P-IRE1a + and XBP1s + cells, in MS lesions, we also detected a significant contribution of neurons, oligodendrocytes, and CD14 + monocytes and microglia ( Figures 6H and 6I ). Collectively, these findings suggest that IRE1a-XBP1 signaling in astrocytes may contribute to MS pathology.
DISCUSSION
The exposome is defined as the totality of environmental exposure of an individual in a lifetime (Wild, 2005) . In this study, we used a novel approach that combines new zebrafish models, bioinformatics, genomics, and in vivo cell-specific genetic perturbations to systematically evaluate the effects of a wide range of common environmental chemicals on CNS inflammation and the molecular mechanisms involved. Our studies identified IRE1a-XBP1 signaling as a driver of genomic programs that contribute to disease-promoting astrocyte activities; IRE1a-XBP1 signaling and, consequently, astrocyte pathogenic activities in EAE were boosted by linuron. Together with previous reports regarding the effects of commensal bacteria-derived metabolites (Erny et al., 2015; Rothhammer et al., 2016 Rothhammer et al., , 2018 Sampson et al., 2016) and changes in melatonin levels induced by seasonal variations in day length (Farez et al., 2015) , our findings support the need for systematic investigation of the effects of the exposome on neurologic diseases. These studies have the potential to identify unknown signaling pathways involved in the control of CNS inflammation and neurodegeneration and also environmental factors that modulate their activation. Future studies should also evaluate additional variables, such as the developmental stage at the time of exposure, a timely concern based on recent reports of the effects of the pesticide chlorpyrifos on CNS development (Rauh, 2018) . In addition, the approach described in this work provides a cost-effective platform to screen for therapeutic compounds that suppress pathogenic activities of CNS-resident cells in their physiologic context.
We defined a role for Sigmar1 in the activation of IRE1a-XBP1driven pathogenic activities in astrocytes by linuron. Sigmar1 is an ER membrane receptor that controls multiple biological processes, including the cellular response to stress and apoptosis (Schmidt et al., 2016) . Interestingly, Sigmar1 has been linked to the pathology of neurologic disorders, such as amyotrophic lateral sclerosis (ALS) (Al-Saif et al., 2011; Tsai et al., 2014) . Indeed, environmental factors contribute to ALS pathogenesis and are considered a potential cause of the sudden increase in ALS incidence detected among young Gulf War veterans (Haley, 2003; Horner et al., 2003) . In this context, our findings suggest that Sigmar1 activation in astrocytes by environmental chemicals may also participate in the pathogenesis of neurologic diseases such as ALS.
Endogenous Sigmar1 agonists have also been identified, including tryptaminergic trace amines, dehydroepiandrosterone, and pregnenolone (Fontanilla et al., 2009) . The regulation of Sigmar1 by endogenous ligands suggests its participation in astrocyte adaptation to the local CNS microenvironment. Interestingly, the ligand-binding cavity in Sigmar1 shows remarkable plasticity in ligand recognition, suggesting that structurally diverse agonists modulate Sigmar1 signaling under physiologic conditions (Schmidt et al., 2016) . In this sense, Sigmar1 resembles the AHR, a ligand-activated transcription factor activated by diverse ligands ranging from pollutants to microbial metabolites. AHR has been shown to control astrocytes in CNS inflammation and is considered a candidate therapeutic target for inflammation and cancer (Gutié rrez-Vá zquez and Quintana, 2018; Wheeler et al., 2017) . Similarly, Sigmar1 may provide a target for the therapeutic modulation of astrocyte responses in MS and other neurologic disorders.
Our studies identify IRE1a-XBP1 signaling as a driver of disease-promoting astrocyte pathogenic activities during CNS inflammation. The UPR has been previously linked to the pathogenesis of neurologic disorders, particularly because of its role within neurons and oligodendrocytes (Hetz and Saxena, 2017) . However, the role of IRE1a-XBP1 signaling as a driver of genomic programs controlling astrocyte pro-inflammatory activities was previously unknown. Our detection of IRE1a-XBP1 activation in MS tissue samples suggests that the UPR in astrocytes contributes to neurodegeneration and disease pathogenesis. Interestingly, PERK activation in oligodendrocytes has been reported to suppress EAE (Lin et al., 2007) . Based on the diverse biological roles of the UPR (Bettigole and Glimcher, 2015; Martinon et al., 2010) , these seemingly conflicting results likely reflect downstream cell-specific UPR functions associated with the specific pathways leading to its activation (e.g., IRE1a versus PERK), the adaptation of different cell types to inflammation (e.g., astrocytes versus oligodendrocytes), and the effects that UPR modulators may have on the inflammatory response (e.g., suppression of pathogenic T cells). Indeed, our data rule out major roles for PERK or ATF6 in astrocyte UPR activation during EAE. Given the heterogeneity of astrocytes in vivo (Ben Haim and Rowitch, 2017; Khakh and Sofroniew, 2015) , IRE1a-XBP1 signaling may be associated with specific populations such as (G and H) Gene set enrichment analysis (G) and pathway analysis (H) of microglia RNA-seq. Ct, Gfap::shScrmbl; KD, Gfap::shXbp1. (I) Nanostring analysis of EAE microglia from Figure 4I . RNA were pooled from n = 5 mice, n = 7 for sgXbp1. All data are shown as mean ± SEM. In all cases, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not statistically significant, p > 0.05. See also Tables S4 and S5 . Cell 176, 581-596, January 24, 2019 591 C3 + neurotoxic astrocytes . These factors should be considered for the design of therapeutic approaches targeting the UPR in neurologic disorders. Microglia and inflammatory monocytes are important contributors to MS pathology (Ajami et al., 2011; Dendrou et al., 2015; Huitinga et al., 1990) . Our data support a role for IRE1a-XBP1 signaling in astrocytes as a driver of genomic programs that control not only astrocyte-intrinsic diseasepromoting activities but also microglia and inflammatory monocytes. Indeed, astrocytes are a source of granulocytemacrophage colony-stimulating factor (GM-CSF) and CCL-2, involved in microglial activation and monocyte recruitment, respectively (Wheeler and Quintana, 2018) . Moreover, recent reports identified astrocytes as a dominant source of signals that polarize myeloid cells in the CNS (Locatelli et al., 2018) . Thus, although much attention has focused on the microglial control of astrocyte activation Rothhammer et al., 2018) , our findings highlight the role of astrocytes in the control of microglia and monocytes and the need to further characterize the molecular mechanisms involved.
Their intrinsic pathogenic activities and their ability to control microglia and monocytes suggest an important role for astrocytes in MS progression, a disease process thought to be driven by CNS-resident cells (Baecher-Allan et al., 2018; Thompson et al., 2018) . Interestingly, IRE1a-XBP1 activation in NAWM and NAGM was predominantly detected in astrocytes. White and gray matter pathology contributes to disease progression in MS, but little is known about the mechanisms involved (Baecher-Allan et al., 2018; Calabrese et al., 2015; Ellwardt et al., 2018; Thompson et al., 2018) . Taken together, these findings suggest that IRE1a-XBP1 signaling in astrocytes participates in pathogenic processes relevant for MS progression. However, because IRE1a-XBP1 activation was also detected in neurons, oligodendrocytes, microglia, and recruited monocytes in MS lesions, this pathway may play additional pathological roles in other cell types besides astrocytes. Indeed, additional pathways, such as PERK, may trigger the UPR in other CNS-resident cells with cell-specific contributions to disease pathology, whereas IRE1a may also activate XBP1-independent pro-inflammatory mechanisms (Bettigole and Glimcher, 2015) .
In conclusion, we describe a novel approach for the systematic investigation of the effects of environmental factors on neuroinflammation. This approach uncovered mechanisms that operate in astrocytes to control CNS inflammation and neurodegeneration as well as environmental exposure that regulate them. This strategy may guide future epidemiologic studies of the effects of the environment on neurologic diseases while identifying molecular mechanisms that control CNS pathology and potential therapeutic targets for MS and other neurologic diseases.
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WT IRE1a Xbp1 splicing analysis Mouse astrocyte cDNA was amplified using Phusion HF PCR Master Mix (#F548L, Thermo Fisher Scientific) using the following primers: forward: 5 0 -AAACAGAGTAGCAGCGCAGACTGC-3 0 and reverse: 5 0 -GGATCTCTAAAACTAGAGGCTTGGTG-3 0 to generate a 598 bp fragment containing a unique PstI restriction enzyme site . For human astrocyte studies, the XBP1 transcript was amplified using the primers: forward: 5 0 -GCGCTGAGGAGGAAACTGAAAAAC-3 0 and reverse: 5 0 -CAGAGGGTATCTC TAAGACTAG-3 0 to generate a 621 bp fragment containing a unique PstI restriction enzyme site.
For human and mouse studies the PCR amplified fragment was purified using a QIAquick PCR Purification Kit (#28104, QIAGEN) and digested using PstI-HF and DpnI in CutSmart Buffer (R3140S, R0176S, New England Biolabs) for 30 minutes at 37C. The cut PCR products were then run on a 0.8% agarose gel for analysis. Densitometry was performed using FIJI (Schindelin et al., 2012) by comparing the ratio of spliced versus unspliced transcript. were: sgXbp1: 5 0 -gGGACACGCTGGATCCTGACG-3 0 , sgErn1: 5 0 -gACATCCTGAGATACGGTGGT-3 0 , sgSigmar1: 5 0 -gGAATGCCG TGGGCCGCGGGA-3 0 , sgEif2ak3: 5 0 -gCTTTGAACTTCGGTATATTC-3 0 , and sgScramble: 5 0 -gGCACTACCAGAGCTAACTCA-3 0 (sequence from #GE100003, Origene).
which was performed in the same manner as mouse samples. Human probes used in this study were: EDEM1 (Hs00976004_m1), NOS2 (Hs01075529_m1), and GAPDH (Hs02758991_g1).
Immunostaining of frozen MS tissue Frozen brain tissue from 4 MS patients and 4 healthy control individuals was cut into 7 mm thick sections, air-dried, and fixed in icecold acetone for 10 minutes. Sections were delipidised in 70% ethanol for 5 minutes, followed by blocking of non-specific binding with 10% donkey serum (#D9663, Sigma-Aldrich). Rabbit anti-human P-IRE1a (#NB100-2323, Novus Biologicals, 1:50) was incubated with mouse anti-human GFAP-Cy3 (#C9205, Sigma-Aldrich, 1:50), mouse anti-human NeuN (#MAB377, Millipore, 1:50), mouse anti-human CNPase (#MAB326, Millipore, 1:100) or mouse anti-human CD14 (#555397, BD Biosciences, 1:10) in blocking buffer overnight at 4C. The next day slides were washed with 0.05% PBS-Tween and incubated with a mixture of donkey anti-rabbit Alexa Fluor 488 (#R37118, Life Technologies, 1:400) and donkey anti-mouse-Cy3 Jackson ImmunoResearch, 1:200) or donkey anti-rabbit-Rhodamine Red X (#711-295-152, Jackson ImmunoResearch, 1:400) and donkey anti-mouse-Alexa Fluor 488 (Jackson ImmunoResearch, 1:400) for 40 minutes at room temperature. Sections were mounted in Mowiol (#81381, Sigma-Aldrich) containing Invitrogen) . In secondary only controls, primary antibodies were omitted to control for non-specific binding.
Immunostaining of paraffin-embedded MS tissue 4 mm thick paraffin embedded brain sections from 4 MS patients and 3 healthy controls were deparaffinised, washed in PBS, and treated with heat-induced antigen retrieval in Tris-EDTA pH = 9. Endogenous avidin/biotin was blocked using an avidin-biotin blocking kit (#004303, Life Technologies) and non-specific binding was further blocked with 10% Goat serum (#G9023, Sigma). Mouse anti-human XBP1s (#MABC521, Millipore, 1:50) was incubated in blocking buffer with 0.1% Triton X-100 overnight at 4C. The next day slides were washed with 1% PBS-Triton X-100 and incubated with goat anti-mouse biotin (#0433, Dako, 1:500), followed by blocking of endogenous peroxidase using 0.3% H2O2 for 15 min. Sections were washed and incubated with streptavidin-HRP (#554066, BD Biosciences, 1:1000) for 40 minutes at room temperature and the signal developed with Tyramide-FITC (#B40953, Life Technologies). After extensive washing, sections were incubated with mouse anti-human GFAP-Cy3 (#C9205, Sigma, 1:50) in blocking buffer for 1 hour at room temperature. Sections were washed again and mounted in Mowiol containing TOPRO-3. In secondary only controls, primary antibodies were omitted to control for non-specific binding. Additional primary antibodies used are: rabbit anti-human NOGO-A (#ab62024, Abcam, 1:200), rabbit anti-human CD14 (#ab133335, Abcam, 1:500), chicken anti-human MAP2 (#ab5392, Abcam, 1:500). Additional secondary antibodies used are: Goat anti-rabbit Cy3 (#111-165-003, Jackson Immunoresearch, 1:300), Goat anti-chicken Alexa 555 (#A21437, Invitrogen, 1:400).
Image acquisition of MS tissue
Images were acquired as z stacks using a Leica SP5 confocal microscope with Leica LAS AF software and processed using FIJI and LAS X. All acquisition settings were kept the same between replicates. P-IRE1a + and XBP1s + cells were quantified per field of view in GFAP+, NeuN+, CNPase+ and CD14+ cell bodies.
Isolation of cells from adult mouse CNS
Astrocytes were isolated by flow cytometry as described Rothhammer et al., 2016) . Briefly, mice were perfused with 1X PBS and the brain was isolated into digestion solution (0.05% Trypsin (#25200-072, Thermo Fisher Scientific), 1 mM EDTA pH = 8.0, in HBSS (#14175, Thermo Fisher Scientific)) and finely chopped with a razor blade. The CNS was incubated at 37C for 10-40 minutes and filtered through a 70 mm cell strainer. Cells were pelleted at 500xg at 4C for 10 minutes in a centrifuge followed by suspension of the pellet in 33% Percoll TM (#17-5445-01, GE Healthcare) in 1X PBS. The suspension was centrifuged at 500xg at 4C for 25 minutes with slow acceleration and deceleration settings to separate myelin and intact cells. Pelleted intact cells were washed with 1X PBS and then stained with antibodies for flow cytometry.
Adult mouse astrocyte cultures
Brains of Gfap(Cre/+);TdTomato(f/+) mice were dissected similar to the described protocol (Foo, 2013) . A single cell suspension was obtained and cells were sorted according to TdTomato fluorescence. Sorted cells were then cultured in poly-L-lysine coated wells in serum-free DMEM/F12 media supplemented with 5 ng/mL heparin-binding EGF-like growth factor (#E4643-50UG, Sigma-Aldrich). Cells were cultured until confluent and then treated with the indicated compounds for 24 hours.
Flow cytometry
Cells were stained in the dark on ice for 15 minutes with flow cytometry antibodies. Cells were then washed once with 1X PBS and resuspended in 1X PBS for sorting as described previously Rothhammer et al., 2016) . Antibodies used in this study were: PE anti-mouse CD45R/B220 (#553089, BD Biosciences, 1:100), PE anti-mouse TER-119 (#116207, Biolegend, 1:100), PE anti-O4 (#FAB1326P, R&D Systems, 1:100), PE anti-CD105 (#12-1051-82, eBioscience, 1:100), PE anti-CD140a (#12-1401-81, eBioscience, 1:100), PE anti-Ly-6G (#127608, Biolegend, 1:100), PerCP anti-Ly-6C (#128028, Biolegend, 1:100), APC anti-CD45 (#17-0451-83, eBioscience, 1:100), APC-Cy7 anti-CD11c (#561241, BD Biosciences, 1:100), and PE-Cy7 or FITC anti-CD11b A) XBP1 expression in glial cells determined by western blot. n = 4 for shXbp1, n = 2 for WT. One-sample t test. (B) IRE1a expression in glial cells determined by western blot. n = 3 per condition. One-sample t test. (C) Xbp1 expression in astrocytes, microglia, or monocytes. n = 5 replicates per condition. Unpaired twotailed t test. D-E) FACS analysis of astrocytes, microglia, and T cells isolated from mice undergoing EAE transduced with Gfap-driven shXbp1 or non-targeting lentiviruses. T cells isolated from the CNS shown in (D) or the spleen shown in (E). n = 10 per condition for astrocytes and microglia, n = 3 per condition for T cells. 
